Bridging the Gap: Integrating Quantitative Systems Pharmacology and Pharmacometrics in Drug Development
- 30 December 2025
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 830-833
Abstract
Quantitative Systems Pharmacology (QSP) and Pharmacometrics (PMX) have historically existed at the two ends of the model‐informed drug development (MIDD) spectrum. The session “Mind the gap ‐ successful bridging of QSP and PMX in drug development” at the 2024 American Conference of Pharmacometrics brought together QSP scientists and pharmacometricians with the aim to develop better understandings of how to bridge this gap. The current perspective is based on the concepts that were presented and the follow‐up panel discussion.Keywords
This publication has 10 references indexed in Scilit:
- Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial CostClinical Pharmacology & Therapeutics, 2025
- Virtual clinical trial simulations using a Quantitative Systems Pharmacology (QSP) model of CDK inhibitors in breast cancer patients2025
- A Novel Two‐Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma PatientsClinical Pharmacology & Therapeutics, 2025
- An integrated quantitative systems pharmacology virtual population approach for calibration with oncology efficacy endpointsCPT: Pharmacometrics & Systems Pharmacology, 2024
- Landscape of regulatory quantitative systems pharmacology submissions to the U.S. Food and Drug Administration: An update reportCPT: Pharmacometrics & Systems Pharmacology, 2024
- Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in OncologyClinical Pharmacology & Therapeutics, 2024
- No Recipe for Quantitative Systems Pharmacology Model Validation, but a Balancing Act Between Risk and CostClinical Pharmacology & Therapeutics, 2023
- Machine Learning‐Based Quantification of Patient Factors Impacting Remission in Patients With Ulcerative Colitis: Insights from Etrolizumab Phase III Clinical TrialsClinical Pharmacology & Therapeutics, 2023
- A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo scoreClinical and Translational Science, 2023
- Pharmacokinetic and Pharmacodynamic Modeling of Serum Etrolizumab and Circulating β7 Receptor Occupancy in Patients With Ulcerative ColitisThe Journal of Clinical Pharmacology, 2017